KTRA has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
KTRA has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Graham Number is a figure that measures a stock's fundamental value by taking into account the company's earnings per share and book value per share. The Graham number is the upper bound of the price range that a defensive investor should pay for the stock. According to the theory, any stock price below the Graham number is considered undervalued, and thus worth investing in.
As of today (2024-05-14), the stock price of Kintara Therapeutics is $0.128. Kintara Therapeutics's graham number for the quarter that ended in Dec. 2023 was $N/A. Therefore, Kintara Therapeutics's Price to Graham Number ratio for today is N/A.
The historical rank and industry rank for Kintara Therapeutics's Graham Number or its related term are showing as below:
Graham Number is a combination of asset valuation and earnings power valuation. It is a very conservative way of valuing a stock.
The historical data trend for Kintara Therapeutics's Graham Number can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kintara Therapeutics Annual Data | |||||||||||||||||||||
Trend | Dec13 | Jun15 | Jun16 | Jun17 | Jun18 | Jun19 | Jun20 | Jun21 | Jun22 | Jun23 | |||||||||||
Graham Number | Get a 7-Day Free Trial | - | - | - | - | - |
Kintara Therapeutics Quarterly Data | ||||||||||||||||||||
Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
Graham Number | Get a 7-Day Free Trial | - | - | - | - | - |
For the Biotechnology subindustry, Kintara Therapeutics's Price-to-Graham-Number, along with its competitors' market caps and Price-to-Graham-Number data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Kintara Therapeutics's Price-to-Graham-Number distribution charts can be found below:
* The bar in red indicates where Kintara Therapeutics's Price-to-Graham-Number falls into.
Graham Number is a concept based on Ben Graham's conservative valuation of companies.
Kintara Therapeutics's Graham Number for the fiscal year that ended in Jun. 2023 is calculated as
Graham Number | |||||
= | sqrt of (22.5 | * | Tangible Book per Share | * | EPS without NRI) |
= | sqrt of (22.5 | * | -5.859 | * | -9.276) |
= | N/A |
Kintara Therapeutics's Graham Number for the quarter that ended in Dec. 2023 is calculated as
Graham Number | |||||
= | sqrt of (22.5 | * | Tangible Book per Share | * | EPS without NRI (TTM)) |
= | sqrt of (22.5 | * | -1.024 | * | -5.957) |
= | N/A |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kintara Therapeutics (NAS:KTRA) Graham Number Explanation
Ben Graham actually did not publish a formula like this. But he wrote in The Intelligent Investor (1948 version) regarding to the criteria for purchases:
Current price should not be more than 15 times average earnings of the past three years.
Current price should not be more than 1.5 times the book value last reported. However, a multiplier of earnings below 15 could justify a correspondingly higher multiplier of assets. As a rule of thumb we suggest that the product of the multiplier times the ratio of price to book value should not exceed 22.5. (This figure corresponds to 15 times earnings and 1.5 times book value. It would admit an issue selling at only 9 times earnings and 2.5 times asset value, etc.)
Unlike valuation methods such as DCF or Discounted Earnings, the Graham number does not take growth into the valuation. Unlike the valuation methods based on book value alone, it takes into account the earnings power. Therefore, the Graham Number is a combination of asset valuation and earnings power valuation.
In general, the Graham number is a very conservative way of valuing a stock. It cannot be applied to companies with negative book values.
Kintara Therapeutics's Price to Graham number Ratio for today is calculated as
Price to Graham number | = | Share Price (Today) | / | Graham number (Q: Dec. 2023 ) |
= | 0.128 | / | N/A | |
= | N/A |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Please keep these in mind:
1. Graham Number does not take growth into account. Therefore it underestimates the values of the companies that have good earnings growth. We feel that if the earnings per share grows more than 10% a year, Graham Number underestimates the value.
2. Graham Number punishes the companies that have temporarily low earnings. Therefore, an average of earnings makes more sense in the calculation of Graham Number.
3. Graham Numbers underestimates companies that are light with book.
Thank you for viewing the detailed overview of Kintara Therapeutics's Graham Number provided by GuruFocus.com. Please click on the following links to see related term pages.
Robert Hoffman | director, officer: President and CEO | ARENA PHARMACEUTICALS INC, 6166 NANCY RIDER DRIVE, SAN DIEGO CA 92121 |
Anthony Scott Praill | officer: Chief Financial Officer | 2001-889 HOMER STREET, VANCOUVER A1 V6B 5S3 |
Saiid Zarrabian | director, officer: Head of Strategic Partnerships | P.O. BOX 675765, RANCHO SANTA FE CA 92067 |
Laura L. Johnson | director | C/O LA JOLLA PHARMACEUTICAL COMPANY, LA JOLLA VILLAGE DRIVE, SUITE 1070, SAN DIEGO CA 92122 |
Tamara A Seymour | director | C/O SIGNAL GENETICS, INC., 5740 FLEET STREET, CARLSBAD CA 92008 |
Toth Robert Joseph Jr | director | 543 LOMBARD ST, SAN FRANCISCO CA 94133 |
Dennis M Brown | officer: Chief Scientific Officer | 100 SAN MATEO DR, MENLO PARK CA 94025 |
Keith Murphy | director | 6275 NANCY RIDGE DRIVE, SUITE 110, SAN DIEGO CA 92121 |
John Liatos | director, officer: SVP, Business Development | 12707 HIGH BLUFF DRIVE, SUITE 200, SAN DIEGO CA 92130 |
John K Bell | director | 38 FALLBROOK LANE RR 33, CAMBRIDGE A6 N3H 4R8 |
Napoleone Ferrara | director | 550 FRONT STREET, UNIT 1103, SAN DIEGO CA 92101 |
Lynda Sarah Cranston | director | 4316 LOCARNO CRESCENT, VANCOUVER A1 V6R 1G3 |
Erich Mohr | director | 8300 GREENSBORO DRIVE, MCLEAN VA 22102 |
Jeffrey Bacha | director | SUITE 3 1545 WEST 14TH AVENUE, VANCOUVER A1 V6J 2J1 |
William J Garner | director | 875 MAHLER ROAD, SUITE 235, BURLINGAME CA 94010 |
From GuruFocus
By PRNewswire PRNewswire • 12-01-2022
By PRNewswire PRNewswire • 10-19-2022
By PRNewswire PRNewswire • 08-09-2022
By PRNewswire • 10-31-2023
By PRNewswire PRNewswire • 06-16-2023
By PRNewswire PRNewswire • 01-09-2023
By PRNewswire PRNewswire • 05-11-2023
By PRNewswire PRNewswire • 04-14-2023
By PRNewswire • 09-18-2023
By PRNewswire PRNewswire • 05-08-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.